Back

GLP1-RA versus metformin as first-line therapy for achieving glycemic control and risk-factor management - a one-year nationwide cohort study

28 August 2023 (15:15 - 15:50)
Organised by: Logo
Congress Presentation Part of: Antidiabetic medications and cardiovascular disease Antidiabetic Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Ms Kathrine Kold Soerensen

North Zealand University Hospital, Copenhagen (Denmark)

6 More presentations in this session

Presentation thumbnail
Effects of SGLT2i on reducing risks of cardiovascular events and dementia in atrial fibrillation patients with diabetes mellitus: a nationwide cohort study
Assistant Professor Y. Chen (Taichung, TW)
Abstract Slides Video
Presentation thumbnail
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular outcomes in patients with atrial fibrillation and type 2 diabetes mellitus
Professor Y. Oh (Seoul, KR)
Abstract Slides
Presentation thumbnail
Comparison of sodium-glucose cotransporter-2 (SGLT2) inhibitors to reduce cardiovascular and renal outcomes: a network meta-analysis of randomized controlled trials
Doctor R. Kani (Kamogawa, JP)
Abstract Slides Video
Presentation thumbnail
The renal outcome post contrast exposure in patient with diabetes and SGLT2 inhibitor
Doctor C. Chen (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Lower risks of sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset hip fracture risks in patients with type-2 diabetes: A propensity sc
Professor G. Tse (Hong Kong, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Antidiabetic medications and cardiovascular disease

The Event

Event poster

ESC Congress 2023

28 August 2023 15:15 CET
You may be interested in
thumbnail
Congress Presentation
Persistence and Adherence to GLP-1 RA treatment in Type 2 Diabetes Mellitus: a Nationwide registry study
thumbnail
Congress Presentation
GLP-1 RAs reduce mortality and cardiovascular events across the spectrum of treated patients: a systematic review and meta-analysis
thumbnail
Congress Presentation
GLP1-RA versus DPP4 inhibitors on cardiovascular outcomes: A three-year real-world analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources